Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867997 · ClinicalTrials.gov registry record · Phase 3
Noncarious Cervical Lesion Treatment Outcomes
A Phase 3 study of Noncarious Cervical Lesions, sponsored by Pearl Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
- 17
- Study locations
NCT00867997: Completed Phase 3 study of Noncarious Cervical Lesions, sponsored by Pearl Network.
NCT00867997 is a Phase 3 study of Noncarious Cervical Lesions that has completed, run by Pearl Network. The registered enrollment target is 304 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 17 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867997, a Phase 3 study of Noncarious Cervical Lesions, has completed, sponsored by Pearl Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
- 17
- Study locations
Study Summary
The overall objective of this three-armed randomized clinical trial (RCT) is to determine the comparative efficacy of three treatments for hypersensitive noncarious cervical lesions (NCLs): chemoactive dentifrice use, dentin bonding agent (DBA) with sealing, and flowable resin-based composite restoration. The primary outcomes of this study are the reduction/elimination of hypersensitivity and the effect of treatment as measured by patient-reported outcomes. Secondary outcomes, as determined by laboratory evaluation of intraoral replicas of pre- and posttreatment NCL surfaces, are tubule occlusion, retention of resin coating, retention of restoration, and change in lesion size. Outcomes will be ascertained via the following specific aims: Specific Aim 1: To compare the reduction of hypersensitivity of study teeth by both measurement and by patient-reported outcomes among three treatment groups. Specific Aim 2: To recruit subjects with teeth with hypersensitive NCLs, measure baseline sensitivity and subject quality of life, administer one of three different treatments to each of three randomized groups of subjects, and determine immediate posttreatment hypersensitivity. Specific Aim 3: To compare the degree of tubule occlusion before and after the three treatments and to associate these findings with posttreatment hypersensitivity, patient-reported outcomes, and restoration retention. Treatment of NCLs remains controversial. Few studies have compared treatment methods or their financial implications. This RCT will determine the reduction of NCL hypersensitivity and patient-reported outcomes over a 6-month period for each of three different treatments. This will be the first practice-based research network RCT to combine objective clinical assessment of NCL treatment patient-reported outcomes with laboratory examination of dentin tubule occlusion and lesion size.
Conditions Studied
Interventions
- OTHER Chemoactive (remineralizing, neuroactive) dentifrice treatment
- OTHER Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F
- OTHER Clearfil S3 Bond; Premise Flowable resin-based composite
Study Locations (17)
New Jersey
- Scott B Schaffer, DMD - Clark
- Gentle Dental Care, LLC - Edison
- Dr. Howard Spielman - Plainsboro
- Drs. Martin & Ferraiolo - Totowa
- Cynthia Jetter, DMD - Voorhees Township
New York
- Bay Dental PC - Brooklyn
- Ying Wong, DDS - New York
- Martin Man, DMD - New York
- Kay T. Oen, DDS - Port Chester
- Janice K. Pliszczak, DDS - Syracuse
Pennsylvania
- Dr. Jeannette Abboud-Niemczyk - Drexel Hill
- Allan J Horowitz, DMD - King of Prussia
- Dr. Julie Ann Barna - Lewisburg
Connecticut
- Maryann Lehmann, DDS - Darien
Maryland
- Ahmad Soolari, D.M.D. - Potomac
Massachusetts
- Oral Health Center - Southborough
Ohio
- Susan D. Bernstein, DDS - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
What the finished NCT00867997 record still lists
NCT00867997 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Noncarious Cervical Lesions appearing as the primary indexed condition, and to 3 interventions - of which Chemoactive (remineralizing, neuroactive) dentifrice treatment is the first listed.
NCT00867997 lists 17 locations in 7 states (New Jersey, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00867997 about?
NCT00867997 is a clinical study titled "Noncarious Cervical Lesion Treatment Outcomes". The overall objective of this three-armed randomized clinical trial (RCT) is to determine the comparative efficacy of three treatments for hypersensitive noncarious cervical lesions (NCLs): chemoactive dentifrice use, dentin bonding agent (DBA) with sealing, and flowable resin-based composite restor...
What is the current status of trial NCT00867997?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2009-03. Estimated completion is 2012-02.
What conditions does trial NCT00867997 study?
This clinical trial studies the following conditions: Noncarious Cervical Lesions.
What interventions are being tested in trial NCT00867997?
The interventions under investigation include: Chemoactive (remineralizing, neuroactive) dentifrice treatment (OTHER), Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F (OTHER), Clearfil S3 Bond; Premise Flowable resin-based composite (OTHER).
Who is sponsoring clinical trial NCT00867997?
This trial is sponsored by Pearl Network, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867997 being conducted?
This trial has 17 study locations across Connecticut, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867997's enrollment target sits among peer trials
304 1117th of 2000 higher than 882 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia